Australia just approved the first new Alzheimer’s treatment in decades. But before patients get their hopes up, there’s a ...

The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

Advisers are of course well placed to help people living with dementia and their families navigate a wide range of issues ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. Vigil shares were trading around $8. The stock was up 36% on the ...

Alzheimer’s researcher Donald Weaver tells The Conversation Weekly podcast what he’s learnt during more than 30 years of studying the disease.

The Alzheimer's Association's Memory Ball Dancing Stars raised a record $1.5 million at its April 26 gala held at the ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Alzheimer’s is a complex disease caused by many interacting factors. It’s possible the herpes virus could play a small role – ...

The first Alzheimer's blood test cleared by the Food and Drug Administration is poised to change the way doctors diagnose and ...

Whether traveling by car or by air, busy holiday weekends can bring anxiety, especially for those traveling with loved ones ...

Whether traveling by car or by air, busy holiday weekends can bring anxiety, especially for those traveling with loved ones ...